[VIEW] agent=Risk & Compliance Officer | scenario_id=120 | rounds=20

--- Round 0 ---
[R0.1] Risk & Compliance Officer (speak, public): To ensure we are aligned on regulatory compliance and patient safety, I would like to discuss the clinical effectiveness of the proposed telehealth anticoagulation management service. Can we review the expected patient outcomes and operational scale? Additionally, I would like to understand how funding and incentives will be structured for this service. Can each of you provide insights on these areas?
[R0.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): Based on our pilot outcomes, we've seen significant improvements in time in therapeutic range (TTR) from 52% to 68% across 180 patients. This indicates a strong potential for the telehealth anticoagulation management service. Additionally, we estimate there are 640 eligible patients per quarter, with a pilot enrollment rate of 28%. I believe these metrics highlight the clinical effectiveness and operational scale we can achieve. Could we also discuss the funding structure and any incentives that may align with these outcomes?
[R0.3] Payer Contracting & Finance Manager (speak, public): Thank you for sharing those insights on the clinical effectiveness and operational scale. To further assess the financial viability, could we clarify the expected demand and staffing intensity for this service? Additionally, I would like to confirm that the legal and vendor terms are aligned to avoid any operational delays. This information will be crucial for our financial assessment.

--- Round 1 ---
[R1.1] Risk & Compliance Officer (speak, public): Thank you for those insights. To address the Payer Contracting & Finance Manager's points, I can share that our vendor security due diligence for the home INR platform revealed a security assessment score of 78/100, and we currently have a Business Associate Agreement with two open clauses. This is crucial for ensuring alignment in our legal and vendor terms. Can we also discuss any potential operational constraints or risks that we should be aware of?
[R1.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the operational constraints, I would like to emphasize that for every 500 active patients, we would require 1.8 pharmacist FTEs and 0.6 RN FTEs. This staffing model is essential for ensuring patient safety and effective management. Additionally, we need to ensure that any unresolved internal risk concerns or commercial constraints are identified early to avoid impacting clinical workflows. Can we discuss any known issues in this regard?
[R1.3] Payer Contracting & Finance Manager (speak, public): Thank you for the detailed insights on operational constraints and staffing needs. Based on our projected volume of 9,600 episodes per year, I would like to discuss how we can align our financial model with the required staffing intensity of 1.8 pharmacists and 0.6 RNs per 500 active patients. Understanding these dynamics will be critical for our financial assessment. Additionally, if we could also address any potential risks associated with this model, it would help us ensure patient safety and operational efficiency.

--- Round 2 ---
[R2.1] Risk & Compliance Officer (speak, public): To ensure a balanced approach, I recommend we outline any unresolved internal risk concerns that may impact the telehealth service's implementation. This includes identifying any potential risks related to patient safety or operational efficiency that we need to address before moving forward. Can we establish a timeframe for resolving these issues to align with our launch plans?
[R2.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I appreciate the emphasis on resolving internal risk concerns. From our perspective, we have not identified any major unresolved issues that could affect patient safety or operational efficiency, but it would be beneficial to conduct a thorough review together. Can we set a timeline for this assessment to ensure we stay on track with our launch plans?
[R2.3] Payer Contracting & Finance Manager (speak, private to=Risk & Compliance Officer,Pharmacy Clinical Lead (Anticoagulation Services)): I appreciate the insights on the lack of major unresolved issues. To ensure we maintain alignment with our launch plans, I suggest we set a timeline for our review and assessment process. This will help us address any potential concerns proactively. How does next week look for a preliminary meeting to outline our review strategy?

--- Round 3 ---
[R3.1] Risk & Compliance Officer (speak, private to=Payer Contracting & Finance Manager,Pharmacy Clinical Lead (Anticoagulation Services)): I agree that setting a timeline for our review and assessment process is crucial. Next week works for me. Could we confirm a specific day and time that accommodates everyone? This will help ensure we stay on track for the launch.
[R3.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, private to=Payer Contracting & Finance Manager,Risk & Compliance Officer): Next week sounds great for our preliminary meeting to outline the review strategy. How about we aim for Wednesday at 2 PM? This should give us enough time to prepare and ensure everyone can attend. I believe this meeting will help us align our efforts effectively as we move towards the launch.
[R3.3] Payer Contracting & Finance Manager (speak, private to=Risk & Compliance Officer,Pharmacy Clinical Lead (Anticoagulation Services)): Wednesday at 2 PM works for me as well. I'll make sure to prepare the necessary financial insights and projections to support our discussion. Let's ensure we have all relevant data ready for that meeting.

--- Round 4 ---
[R4.1] Risk & Compliance Officer (leave, public): 
[R4.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R4.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 5 ---
[R5.1] Risk & Compliance Officer (leave, public): 
[R5.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R5.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 6 ---
[R6.1] Risk & Compliance Officer (leave, public): 
[R6.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R6.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 7 ---
[R7.1] Risk & Compliance Officer (leave, public): 
[R7.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R7.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 8 ---
[R8.1] Risk & Compliance Officer (leave, public): 
[R8.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R8.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 9 ---
[R9.1] Risk & Compliance Officer (leave, public): 
[R9.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R9.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 10 ---
[R10.1] Risk & Compliance Officer (leave, public): 
[R10.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R10.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 11 ---
[R11.1] Risk & Compliance Officer (leave, public): 
[R11.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R11.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 12 ---
[R12.1] Risk & Compliance Officer (leave, public): 
[R12.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R12.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 13 ---
[R13.1] Risk & Compliance Officer (leave, public): 
[R13.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R13.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 14 ---
[R14.1] Risk & Compliance Officer (leave, public): 
[R14.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R14.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 15 ---
[R15.1] Risk & Compliance Officer (leave, public): 
[R15.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R15.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 16 ---
[R16.1] Risk & Compliance Officer (leave, public): 
[R16.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R16.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 17 ---
[R17.1] Risk & Compliance Officer (leave, public): 
[R17.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R17.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 18 ---
[R18.1] Risk & Compliance Officer (leave, public): 
[R18.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R18.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 19 ---
[R19.1] Risk & Compliance Officer (leave, public): 
[R19.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R19.3] Payer Contracting & Finance Manager (leave, public): 

